New Service: Alicanto for Antibody Discovery from Human Serum
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!
Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!
Click below to watch the presentation.
Related Posts
De Novo Antibody Sequencing: Which Enzymes are Best?
De novo antibody sequencing is the process of determining the primary amino acid sequence of an antibody directly from the protein. Determining the sequence of an antibody is a requirement for many downstream activities. Intellectual Property Protection: In order to...
Can You Sequence an Antibody?
What does it mean to sequence an antibody?Antibodies are tetrameric proteins comprised of two identical heavy chains and two identical light chains. One naturally occurring exception to this is the heavy chain-only antibodies produced by camelids and cartilaginous...
FASTA2AIRR: comparing human and humanized antibodies
Fasta2airr is a free web app for converting antibody sequences into annotated AIRR-Seq files. Converting sequences into this open format is an essential step in antibody repertoire analysis. Among other antibody meta data the AIRR-Seq file contains: Germline gene...
Get In Touch